These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9466087)

  • 21. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A; Soares HP; Caparroz C; Castro PC
    Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    Lindley C; Blower P
    Am J Health Syst Pharm; 2000 Sep; 57(18):1685-97. PubMed ID: 11006796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
    Seynaeve C; Verweij J; de Mulder PH
    Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
    Coppes MJ; Yanofsky R; Pritchard S; Leclerc JM; Howard DR; Perrotta M; Keays S; Pyesmany A; Dempsey E; Pratt CB
    J Pediatr Hematol Oncol; 1999; 21(4):274-83. PubMed ID: 10445889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are there differences among the serotonin antagonists?
    Tonato M; Roila F; Del Favero A
    Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
    Del Favero A; Roila F; Tonato M
    Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
    Gan TJ
    CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute emesis: moderately emetogenic chemotherapy.
    Herrstedt J; Koeller JM; Roila F; Hesketh PJ; Warr D; Rittenberg C; Dicato M
    Support Care Cancer; 2005 Feb; 13(2):97-103. PubMed ID: 15565276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
    Jones AL; Lee GJ; Bosanquet N
    Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.
    Jantunen IT; Kataja VV; Muhonen TT
    Eur J Cancer; 1997 Jan; 33(1):66-74. PubMed ID: 9071902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.